1stOncology™: Cancer Intelligence Service – Page 2847 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

GSK delivers continued strong performance and upgrades 2024 guidance

On July 31, 2024 GlaxoSmithKline reported the company continued strong performance and upgrades 2024 guidance (Press release, GlaxoSmithKline, JUL 31, 2024, View Source [SID1234645484]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

On July 31, 2024 AbCellera (Nasdaq: ABCL) reported that it has expanded its existing collaboration with Eli Lilly and Company (Lilly) to discover therapeutic antibodies for programs in immunology, cardiovascular disease, and neuroscience (Press release, AbCellera, JUL 31, 2024, View Source [SID1234645220]). The expansion builds upon the successful research collaboration established in March 2020, which included eight de novo programs for targets selected by Lilly and an exclusive license to AbCellera’s COVID-19 antibody program.

AbCellera has advanced all eight programs under the original agreement, and the licensed program resulted in emergency use authorization by the U.S. Food and Drug Administration for two COVID-19 antibody therapies co-developed by the companies.

"Lilly has been a terrific partner and is one of the most admired and innovative pharmaceutical companies in the world," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "We are excited to deepen our partnership and potentially increase our impact on patients across multiple therapeutic areas."

Under the expanded agreement, Lilly has the right to develop and commercialize therapeutic antibodies resulting from the collaboration. AbCellera has received an upfront payment, will receive research payments, and is eligible to receive downstream milestone payments and royalties on net product sales.

Tvardi Therapeutics to Participate at the 2024 BTIG Virtual Biotechnology Conference

On July 31, 2024 Tvardi Therapeutics, Inc. ("Tvardi"), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, reported that Imran Alibhai, PhD, Chief Executive Officer of Tvardi Therapeutics will participate in a fireside chat at the 2024 BTIG Virtual Biotechnology Conference on Tuesday, August 6, 2024, at 10:00 AM ET (Press release, Tvardi Therapeutics, JUL 31, 2024, View Source [SID1234645219]).

In addition to the fireside chat, the management team will hold one-on-one investor meetings Monday and Tuesday, August 5-6, 2024. If you are interested in meeting with the Tvardi Therapeutics management team during the conference, please reach out to BTIG.

Personalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference

On July 31, 2024 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, reported that its management team will participate virtually at the 9th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference on Tuesday, August 13, 2024 (Press release, Personalis, JUL 31, 2024, View Source;1-Conference [SID1234645218]).

CREATV BIO ANNOUNCES ITS CAML BIOMARKER INCLUDED IN PIVOTAL PHASE 3 TRIAL IN METASTATIC BREAST CANCER

On July 31, 2024 Creatv Bio, a Division of Creatv MicroTech, Inc. (Creatv) reported that its Cancer Associated Macrophage-Like (CAML) liquid biopsy biomarker has been included as part of the pivotal Phase 3 trial of BriaCell Therapeutics Corporation’s lead clinical candidate, Bria-IMT in combination with an immune checkpoint inhibitor in metastatic breast cancer (Press release, CREATV MICROTECH, JUL 31, 2024, View Source [SID1234645217]).

This study is expected to enroll a total of 404 patients in two arms – Bria-IMT in combination with an immune checkpoint inhibitor versus treatment of physicians’ choice in late-stage metastatic breast cancer patients, with no approved alternative therapies available (listed on ClinicalTrials.gov as NCT06072612). Bria-IMT was awarded Fast Track status by the U.S. Food and Drug Administration (FDA).

Blood samples are being provided to Creatv to analyze for the presence of circulating tumor cells (CTCs), CAML subtyping, and to monitor PD-L1 upregulation in patients. The samples are being taken at baseline and at a designated time following the initial patient treatment.

Creatv previously demonstrated that CAMLs can accurately (i) predict a cancer’s aggressiveness as well as multi-organ metastasis, (ii) provide a universal companion diagnostics tool using blood instead of tissue from patients, (iii) predict treatment response within approximately 30 days of receiving a new therapy in any solid tumor type, (iv) detect minimal residual disease, and (v) cancer recurrence.

"The use of biomarkers like CAMLs holds great promise in helping clinicians determine whether a patient is responding to a specific therapy in a timely manner," remarked Dr. Cha-Mei Tang, President and CEO of Creatv Bio. "We are looking forward to participating in this important trial with BriaCell and are confident that as a result, this biomarker will provide clinicians with a valuable tool to guide their treatment choices for cancer patients."